BOSTON–(BUSINESS WIRE)–#artificialintelligence–LabMinds, Inc., a next-generation robotics company focused on solution preparation, announces that Jeff Caputo has been named as President and Chief Executive Officer and a Member of the Board of Directors.
Jeff brings over 18 years of experience in the life science industry in a variety of commercial, investing and operating roles, most recently as Founder and Chief Executive Officer of Invisio Medical, Inc. Prior to this, Jeff was Chief Executive Officer of Cephalogics, LLC, an Allied Minds portfolio company after being a member of the Allied Minds, Inc. life sciences investment team as their Director of Life Sciences. Before joining Allied Minds, Jeff held sales and marketing management roles at Aspect Medical Systems which was acquired by Covidien in 2009.
“Jeff has the leadership, business experience and track record essential to lead LabMinds,” said John Kawola, Chairman of the Board at LabMinds, “including sales, marketing, business development, and operations. His life science experience building and commercializing capital systems that utilize Artificial Intelligence and Machine Learning is a great fit for us. Speaking on behalf of the board, we look forward to working closely with Jeff as CEO.”
“I am excited to join the LabMinds team and lead the company into its next phase focused on commercial growth,” said Jeff Caputo. “We have an innovative technology and an exceptionally talented team at LabMinds. Together we’ll focus on driving growth through market expansion and launching new products.”
Jeff received a BA in Biology and Psychology from St. Olaf College and an MBA in Venture Capital and Entrepreneurial Management from Boston College.
LabMinds is the leader in AI and robotics for solution preparation in pharmaceutical and life science labs. A cornerstone of R&D and QA/QC processes, solution preparation continues to be a highly manual process with many moving parts, exposing labs to considerable risk and inevitable waste. LabMinds’ platform addresses these challenges with powerful AI software combined with state-of-the-art robotics to safeguard against tainted inputs, enable near-perfect accuracy, and attain unmatched control. Further, labs in the LabMinds network contribute to, and benefit from, the collection of input and sensor data throughout the solution prep process; it’s never been easier to gain detailed insight into how chemicals interact with each other. By implementing more security and order, and leveraging the power of big data, LabMinds moves ever closer to achieving its mission to enable scientists and businesses to build and optimize labs, to bring meaningful therapies to market sooner. For more information, please visit www.LabMinds.com.
Guenolee Ribadeau Dumas